Guidelines recommend initiating basal insulin in people with uncontrolled type 2 diabetes (T2D), as reflected by high glycated haemoglobin A1c (A1C) levels, or inability to achieve target A1C levels on oral antidiabetes drugs (OADs) and/or glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs).1, 2. The gene discussed is INS; the disease is type 2 diabetes mellitus.